Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494570 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
A Phase 2 study, sponsored by Aadi Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02494570 is a Phase 2 study that has completed, run by Aadi Bioscience. The registered enrollment target is 34 participants.
The verdict
NCT02494570, a Phase 2 study, has completed, sponsored by Aadi Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
Interventions
- DRUG nab-Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-10 |
| Est. Completion | 2022-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02494570
The ClinicalTrials.gov registry entry for NCT02494570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nab-Sirolimus is the first listed.
NCT02494570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02494570 about?
NCT02494570 is a clinical study titled "A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa". A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
What is the current status of trial NCT02494570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2015-10. Estimated completion is 2022-04.
What interventions are being tested in trial NCT02494570?
The interventions under investigation include: nab-Sirolimus (DRUG).
Who is sponsoring clinical trial NCT02494570?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.